EXAGEN INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- EXAGEN INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- EXAGEN INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 0.00 shares.
- EXAGEN INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 0.00 shares.
- EXAGEN INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 0.00 shares.
- EXAGEN INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 108.00 shares, a 99.87% decline from fiscal 2024.
- EXAGEN INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 85.12K shares, a 8.80% decline from fiscal 2023.
- EXAGEN INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 93.33K shares, a 61.93% decline from fiscal 2022.
- EXAGEN INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 245.19K shares, a 1951.77% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | 0.00 shares derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-11 | 108.00 shares derived: sum of 4 quarters · filed 2026-05-11 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | 108.00 shares 10-K · filed 2026-03-10 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | |
| 2025-06-30 | 108.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-29 | |
| 2025-03-31 | 0.00 shares 10-Q · filed 2026-05-11 | |
| 2024-12-31 | 85.12K shares 10-K · filed 2025-03-11 | |
| 2023-12-31 | 93.33K shares 10-K · filed 2024-03-18 | |
| 2022-12-31 | 245.19K shares 10-K · filed 2023-03-20 | |
| 2021-12-31 | 11.95K shares 10-K · filed 2022-03-22 | |
| 2020-12-31 | 195.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | 47.55K shares 10-K · filed 2021-03-16 |
| 2020-09-30 | 55.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | 48.85K shares derived: sum of 4 quarters · filed 2020-11-10 |
| 2020-06-30 | 3.60K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-28 | |
| 2020-03-31 | 43.70K shares 10-Q · filed 2020-05-11 | |
| 2019-12-31 | 1.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-25 | 1.55K shares 10-K · filed 2020-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |